These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12040475)

  • 1. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
    Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
    Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
    van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
    Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
    Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL.
    Hess G; Flohr T; Derigs HG
    Ann Hematol; 2002; 81 Suppl 2():S54-5. PubMed ID: 12611079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
    Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma.
    Endo T; Sato N; Mogi Y; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Ikeda H; Koike T
    Bone Marrow Transplant; 2004 Apr; 33(7):703-7. PubMed ID: 14743197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
    Hess G; Flohr T; Kolbe K; Bonn S; Schuler M; Derigs HG; Huber C
    Ann Hematol; 2006 Nov; 85(11):769-79. PubMed ID: 16896912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
    Joyce RM; Kraser CN; Tetrealt JC; Giallombardo N; McDermott D; Levine J; Umiel T; Regan M; Hurley D; Uhl L; Avigan D
    Eur J Haematol Suppl; 2001 Jul; 64():56-62. PubMed ID: 11486404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
    Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
    Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Kim SW; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Transfusion; 2007 Aug; 47(8):1447-54. PubMed ID: 17655589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
    Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
    Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
    Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
    Pettengell R
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S1-4. PubMed ID: 11840153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.
    Tsirigotis P; Dray L; Resnick IB; Ackerstein A; Gesundheit B; Elad S; Or R; Shapira MY
    Ann Hematol; 2010 Mar; 89(3):263-72. PubMed ID: 19693502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
    Kamezaki K; Kikushige Y; Numata A; Miyamoto T; Takase K; Henzan H; Aoki K; Kato K; Nonami A; Kamimura T; Arima F; Takenaka K; Harada N; Fukuda T; Hayashi S; Ohno Y; Eto T; Harada M; Nagafuji K
    Bone Marrow Transplant; 2007 May; 39(9):523-7. PubMed ID: 17369863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas.
    Tóthová E; Kafková A; Guman T; Stecová N; Fricová M
    Neoplasma; 2003; 50(1):22-5. PubMed ID: 12687274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.